ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,047 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 201-225 of 1,000 matching filings.

Per page
25
Current page
9
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
07 Mar 2025
Reporting date
07 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

NOTICE OF AGM

Filing date
07 Mar 2025
Reporting date
07 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER

Filing date
07 Mar 2025
Reporting date
07 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORM 6-K

Filing date
07 Mar 2025
Reporting date
07 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
06 Mar 2025
Reporting date
06 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
05 Mar 2025
Reporting date
05 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Mar 2025
Reporting date
03 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN

Filing date
03 Mar 2025
Reporting date
03 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER

Filing date
28 Feb 2025
Reporting date
28 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER

Filing date
26 Feb 2025
Reporting date
26 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FILING OF FORM 20-F WITH SEC

Filing date
19 Feb 2025
Reporting date
19 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
IRANNOTICE File 001-11960

IRANNOTICE

Filing date
18 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORM 6-K

Filing date
18 Feb 2025
Reporting date
18 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
18 Feb 2025
Reporting date
18 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ANNUAL FINANCIAL REPORT

Filing date
18 Feb 2025
Reporting date
18 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTORATE CHANGE

Filing date
18 Feb 2025
Reporting date
18 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FINAL RESULTS

Filing date
06 Feb 2025
Reporting date
06 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-284374

EFFECT filing

Filing date
05 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Feb 2025
Reporting date
03 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC

Filing date
03 Feb 2025
Reporting date
03 Feb 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN US FOR BREAST CANCER POST ET

Filing date
28 Jan 2025
Reporting date
28 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
24 Jan 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
F-6 File 333-284374

F-6 filing

Filing date
21 Jan 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER

Filing date
21 Jan 2025
Reporting date
21 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .